Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Outlines Streamlined Development Path For Targeted Therapies

Executive Summary

But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.

Advertisement

Related Content

Vitrakvi, Daurismo Approvals Put US FDA On Brink Of Another Record
Antibiotic Development Question: Should A Phage Library Equal One Application?
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA's Top Tips For Tumor Agnostic Drug Development
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications
Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine
Tissue-Agnostic Approach To Cancer Drug Development Takes A Hit
Lessons From Avastin: Accelerated Approval Needs “Easy On, Easy Off” Mechanism, Pazdur Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel